Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010--11. MMWR 2010; 59 (31): 989-992.

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Superseded

This Document Has Been Replaced By: Prevention and control of seasonal influenza with vaccines : recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 influenza season

Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010--11. MMWR 2010; 59 (31): 989-992.

August 13, 2010
By United States. Advisory Committee on Immunization Practices.
Source: MMWR. Morbidity and mortality weekly report. 2010; 59(31):989-92.

[PDF-305.76 KB]

English

Details You May Also Like

Details:

Alternative Title:

MMWR. Morbidity and mortality weekly report
Corporate Authors:

United States. Advisory Committee on Immunization Practices.
Description:

During the 2010 influenza season in Australia, administration of a 2010 Southern Hemisphere seasonal influenza trivalent inactivated vaccine (TIV) (Fluvax Junior and Fluvax) manufactured by CSL Biotherapies was associated with increased frequency of fever and febrile seizures in children aged 6 months through 4 years. Postmarketing surveillance indicated increased reports of fever in children aged 5-8 years after vaccination with Fluvax compared to previous seasons. An antigenically equivalent 2010-11 Northern Hemisphere seasonal influenza TIV (Afluria) manufactured by CSL Biotherapies is approved by the Food and Drug Administration (FDA) for persons aged >or=6 months in the United States. Prescribing information for the 2010-11 Afluria formulation includes a warning that "Administration of CSL's Southern Hemisphere influenza vaccine has been associated with increased postmarketing reports of fever and febrile seizures in children predominantly below the age of 5 years as compared to previous years". In the United States, annual influenza vaccination is recommended for all persons aged >or=6 months. On August 5, 2010, the Advisory Committee on Immunization Practices (ACIP) recommended that the 2010-11 Afluria vaccine not be administered to children aged 6 months through 8 years. Other age-appropriate, licensed seasonal influenza vaccine formulations should be used for prevention of influenza in these children. If no other age-appropriate, licensed inactivated seasonal influenza vaccine is available for a child aged 5-8 years who has a medical condition that increases their risk for influenza complications, Afluria can be used; however, providers should discuss with the parents or caregivers the benefits and risks of Afluria use before administering this vaccine to children aged 5-8 years.
Subjects:

[+]

Child Child, Preschool Fever Humans Infant Influenza, Human Influenza Vaccines Product Surveillance, Postmarketing Risk Factors Seizures, Febrile
Source:

MMWR. Morbidity and mortality weekly report. 2010; 59(31):989-92.
Pubmed ID:

20703207
Document Type:

Journal Article
Place as Subject:

Australia ; New Zealand ; United States

Australia ; New Zealand ; United States Less -
Volume:

59
Issue:

31
Collection(s):

Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report (MMWR) Guidelines and Recommendations
Main Document Checksum:

[+]

urn:sha256:971da6bc0576f4463d4a02410e1df4afc45c77f485b78af306d37a4a1a94fdd0
Download URL:

https://stacks.cdc.gov/view/cdc/7452/cdc_7452_DS1.pdf
File Type:

No Additional Files

More +

Superseded

Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010--11. MMWR 2010; 59 (31): 989-992.

Details:

Supporting Files

You May Also Like